Comprehensive review defining clinical approach, classification, and treatment
Key clinical evidence
Weinshenker BG et al. Randomized trial of plasma exchange in steroid-refractory CNS demyelinating disease
42% moderate-to-marked improvement with PLEX vs 6% with sham
Jonsson DI et al. Incidence, etiology, and long-term outcome of acute myelitis in Stockholm County
Neurology Neuroimmunology and Neuroinflammation. 2025
Gastaldi M et al. Predictors of outcome in a large retrospective cohort of patients with TM
Multiple Sclerosis. 2018. Spinal shock as key poor prognostic indicator
Mariano R et al. Comparison of clinical outcomes of TM among adults with MOG-IgG vs AQP4-IgG disease
JAMA Network Open. 2019
Subspecialty sources
Ciccarelli O et al. Spinal cord involvement in MS and NMOSD. Lancet Neurology 2019
Absoud M, Greenberg BM et al. Pediatric transverse myelitis. Neurology 2016
Zalewski NL, Flanagan EP, Keegan BM. Evaluation of idiopathic TM revealing specific myelopathy diagnoses. Neurology 2018
Cortese R et al. Differentiating MS from AQP4-NMOSD and MOG-antibody disease with imaging. Neurology 2023
ICD-10 coding reference
G37.3 Acute transverse myelitis in demyelinating disease of central nervous system
G04.89 Other myelitis (acute transverse myelitis, idiopathic)
G36.0 Neuromyelitis optica (Devic disease)
G35 Multiple sclerosis
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.